Hospira to Handle Fill-Finish Operations for Genzyme's Multiple Drugs - - BioPharm International

ADVERTISEMENT

Hospira to Handle Fill-Finish Operations for Genzyme's Multiple Drugs



Genzyme Corp (Cambridge, MA), which has been trying to resolve its manufacturing problems at its Allston Landing plant last June, has signed a new supply agreement with Hospira Inc (Lake Forest, Illinois) for fill-finish operations of seven products, according to a recent report by Reuters.

In May, Genzyme agreed to terms of a consent decree with the FDA, which requires the company to move its fill-finish operations out of the Allston Landing plant for Cerezyme, Fabrazyme, and Thyrogen, and Myozyme. Under the new agreement, Hospira will now also handle the fill-finish operations for Lumizyme, Thymoglobulin, Campath, and other products now being developed by Genzyme.

Under the terms of the consent decree Genzyme also will pay the government $175 million in profits from past sales of certain drugs.

Previous coverage:
Genzyme Expects $175 Million Fine

Genzyme to Exit Fill-Finish Operations at Allston Landing Plant

FDA Takes Enforcement Action Regarding Genzyme's Allston Plant

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines

Click here